{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Successful PBSC collection was defined as a collection of more than 2x10\\^6 CD34 positive cells.","groups":[{"description":"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.\n\nBrentuximab Vedotin: Given IV\n\nGemcitabine Hydrochloride: Given IV","id":"OG000","title":"Treatment (Brentuximab Vedotin, Gemcitabine Hydrochloride)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"For 21 of the eligible 45 subjects, PBSC collection was not attempted during protocol therapy, either because stem cells had been collected prior to study enrollment, or no autologous stem cell transplant was planned. 1 patient was ineligible due to exceeding the prescribed interval between disease evaluation and study entry.","reportingStatus":"POSTED","timeFrame":"From 1 to 5 cycles","title":"The Number of Patients Who Had Successful Peripheral Blood Stem Cell (PBSC) Collection","type":"SECONDARY","unitOfMeasure":"Participants"}